Lydia Ritter
Overview
Explore the profile of Lydia Ritter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schewe K, Cooper S, Crowe J, Llewellyn S, Ritter L, Ryan K, et al.
Vaccines (Basel)
. 2024 Nov;
12(11).
PMID: 39591178
Between 2013 and 2016, the A/H1N1pdm09 component of the live attenuated influenza vaccine (LAIV) produced instances of lower-than-expected vaccine effectiveness. Standard pre-clinical ferret models, using a human-like vaccine dose and...
2.
Dempsey R, Ritter L, Parker L
J Gen Virol
. 2022 Nov;
103(11).
PMID: 36409607
The vaccine effectiveness (VE) of the A/H1N1pdm09 component of the 2017-18 quadrivalent live attenuated influenza vaccine (QLAIV) was improved by performing rational haemagglutinin (HA) mutagenesis. Introducing N125D, D127E, D222G and...
3.
Hawksworth A, Lockhart R, Crowe J, Maeso R, Ritter L, Dibben O, et al.
Vaccine
. 2020 May;
38(26):4209-4218.
PMID: 32376111
In the 2013-2014 and 2015-2016 influenza seasons, live attenuated influenza vaccine (LAIV) generated reduced vaccine effectiveness (VE) against circulating H1N1 strains. This reduced VE coincided with the introduction of pandemic...
4.
Parker L, Ritter L, Wu W, Maeso R, Bright H, Dibben O
Vaccine
. 2019 Jul;
37(32):4543-4550.
PMID: 31279567
During the 2013-2014 influenza season, the quadrivalent live attenuated influenza vaccine (QLAIV), had lower than expected vaccine effectiveness (VE) against circulating A/H1N1pdm09 viruses in the USA. The underlying reason proposed...